According to our recent payer coverage analysis for prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for prostate cancer treatments shows that under the pharmacy benefit, almost half of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In December 2019, the FDA granted another indication to Xtandi (enzalutamide) for the treatment of men with metastatic castrationsensitive prostate cancer.